HC Wainwright reissued their buy rating on shares of MiNK Therapeutics (NASDAQ:INKT – Free Report) in a report released on Wednesday, Benzinga reports. The brokerage currently has a $9.00 price target on the stock. MiNK Therapeutics Price Performance MiNK Therapeutics stock opened at $0.67 on Wednesday. The business has a 50 day moving average of […]

HC Wainwright restated their buy rating on shares of Unicycive Therapeutics (NASDAQ:UNCY – Free Report) in a report released on Wednesday, Benzinga reports. They currently have a $2.50 target price on the stock. UNCY has been the subject of a number of other reports. Benchmark reissued a speculative buy rating and set a $3.00 price […]

HC Wainwright reaffirmed their neutral rating on shares of Sage Therapeutics (NASDAQ:SAGE – Free Report) in a report released on Wednesday morning, Benzinga reports. HC Wainwright currently has a $25.00 price target on the biopharmaceutical company’s stock. Other equities research analysts also recently issued reports about the company. Scotiabank dropped their target price on Sage […]

HC Wainwright restated their buy rating on shares of Regulus Therapeutics (NASDAQ:RGLS – Free Report) in a research report report published on Tuesday, Benzinga reports. HC Wainwright currently has a $10.00 price target on the biopharmaceutical company’s stock. Several other analysts also recently commented on RGLS. Canaccord Genuity Group raised their price objective on shares […]